XXXX -reported outcomes after electron radiation treatment for early-stage palmar and @entity23808 .

@entity1 @entity2597 @entity137 @entity66 @entity23808 @entity1161 @entity158
PURPOSE: @entity23808 ( @entity23808 ) is a progressive @entity2597 of the hand/foot that often leads to debilitating functional impairment. In Europe, orthovoltage @entity1161 ( @entity1161 ) has been demonstrated to prevent @entity66 progression for up to 80% of @entity1 with early-stage @entity23808 . There are limited data reporting outcomes for populations outside of Europe or using electron @entity1161 . METHODS AND MATERIALS: Between 2008 and 2013, 44 early-stage @entity23808 cases received @entity1161 . @entity1161 fields involved clinically defined targets encompassing involved areas (skin changes, cords, nodules) with at least 1.5-cm margins. En face electrons (6-12 MeV) and bolus (0.5-1 cm) were selected individually. Outcomes are reported for @entity1 who participated in an institutional review board-approved standardized questionnaire and chart review. RESULTS: Thirty-three @entity1 received 66 treatments (45 hands/15 feet and 6 reirradiations). Most frequent dose schemes were 21 Gy (3 Gy in 7 fractions) and 30 Gy (3 Gy in 10 fractions with 6- to 8-week breaks after 15 Gy). Median time to follow-up survey was 31 months. Disease progression at any location within or outside the @entity1161 treatment field occurred in 20 of 33 @entity1 (61%). Fourteen of 60 sites (23%) developed in-field progression, but 4 sites were successfully reirradiated with final local control in 50 of 60 sites (83%). @entity1161 improved pretreatment symptoms of @entity158 with strain at 30 of 37 sites (81%) and itch/burn sensations at 17 of 21 sites (81%). There were no reported grade >= 2 late @entity137 even with reirradiation. @entity1 reported overall success with treatment was 31 of 33 @entity1 (94%). CONCLUSION: @entity23808 is a progressive disease. En face electron @entity1161 is an effective therapy that stabilizes or improves symptoms in the majority of @entity1 . Reirradiation can be considered as a treatment option for in-field progression. @entity1 report minimal @entity137 and a high rate of satisfaction with treatment.
